Table 3.
Outcomes of the febuxostat group and comparisons on the use of diuretics
| No diuretics (n = 14 (42.4%)) |
Diuretics (n = 19 (57.6%)) |
P | |
|---|---|---|---|
| Primary outcome variable | |||
| Maximum dose of febuxostat (mg/day) | 80.0 (70.0–80.0) | 80.0 (40.0–80.0) | 0.398 |
| Secondary outcome variables | |||
| Baseline SU (mg/dL) | 8.7 (7.6–9.6) | 9.6 (8.0–11.4) | 0.174 |
| Final SU (mg/dL) | 3.5 (2.5–4.9) | 3.9 (3.4–5.1) | 0.439 |
| Final eGFR (ml/min) | 49.1 (37.3–69.1) | 30.5 (19.0–42–9) | 0.004 |
| SU reduction (mg/dL) | 5.0 (2.5–5.6) | 4.5 (3.9–6.3) | 0.733 |
| Achievement of SU targets | |||
| - SU <6 mg/dl, n (%) | 11 (78.6) | 17 (81.0) | 1.000 |
| - SU <5 mg/dl, n (%) | 11 (78.6) | 14 (66.7) | 0.445 |
| - SU <4 mg/dl, n (%) | 8 (57.1) | 11 (52.4) | 0.782 |
Data shown as median (IQR) unless specified otherwise. In bold, statistically significant differences between subgroups. eGFR estimated glomerular filtration rate, SU serum urate